Stockscreener 앱 받기
6.96
11.68%
-0.92
시간 외 거래:
6.97
0.010
+0.14%
전일 마감가:
$7.88
열려 있는:
$7.95
하루 거래량:
1.50M
Relative Volume:
1.64
시가총액:
$478.74M
수익:
$6.96M
순이익/손실:
$-46.51M
주가수익비율:
-85.29
EPS:
-0.0816
순현금흐름:
$-37.99M
1주 성능:
-37.24%
1개월 성능:
-44.98%
6개월 성능:
-56.50%
1년 성능:
+167.49%
1일 변동 폭
$6.79
$7.95
1주일 범위
$6.79
$11.17
52주 변동 폭
$2.28
$19.05
Perspective Therapeutics Inc Stock (CATX) Company Profile
명칭
Perspective Therapeutics Inc
전화
509-375-1202
주소
350 Hills Street, Suite 106, Richland
CATX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| CATX | 6.96 | 478.74M | 6.96M | -46.51M | -37.99M | -0.0816 |
| ABT | 117.36 | 202.64B | 41.22B | 5.77B | 6.49B | 2.94 |
| SYK | 389.40 | 150.72B | 21.97B | 3.59B | 3.21B | 6.74 |
| BSX | 90.45 | 133.82B | 15.91B | 1.79B | 1.89B | 0.82 |
| MDT | 87.59 | 112.98B | 32.58B | 3.93B | 5.15B | 2.71 |
| EW | 69.89 | 40.52B | 6.60B | 4.16B | 490.10M | 2.34 |
Perspective Therapeutics Inc 주식(CATX)의 최신 뉴스
CATX FY2024 EPS Estimate Boosted by Cantor Fitzgerald - MarketBeat
Is Perspective Therapeutics (CATX) the Best Multibagger Stock to Buy Heading into 2025? - Yahoo Finance
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024 - The Manila Times
Avidity Partners Management LP Bolsters Portfolio with Perspecti - GuruFocus.com
Analysis of COMMODORE CAPITAL LP's Recent Transaction in Perspec - GuruFocus.com
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Janus Henderson Group PLC Increases Stake in Perspective Therape - GuruFocus.com
Perspective Therapeutics' SWOT analysis: radiopharmaceutical stock's potential in focus - Investing.com
Perspective Therapeutics' SWOT analysis: radiopharmaceutical stock's potential in focus By Investing.com - Investing.com UK
Perspective Therapeutics earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Perspective Therapeutics: Q3 Earnings Snapshot - Houston Chronicle
Perspective Therapeutics Reports Strong Cash Position and Clinical Advances - TipRanks
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results - The Manila Times
Perspective Therapeutics Reports $267.8M Cash Position, Advances Cancer Drug Trials | CATX Stock News - StockTitan
Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings) - Benzinga
WealthPlan Investment Management LLC Invests $4.53 Million in Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat
FMR LLC Acquires Shares in Perspective Therapeutics Inc - GuruFocus.com
Lantheus Reports Third Quarter 2024 Financial Results - The Manila Times
Perspective Therapeutics, Inc. (NYSE:CATX) Receives $20.63 Consensus Price Target from Analysts - MarketBeat
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Perspective Therapeutics management to meet virtually with Cantor Fitzgerald - Nasdaq
Perspective Therapeutics targeting tumors - The Gazette
Hills Bank & Trust Co Takes $13.72 Million Position in Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results - The Manila Times
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights - Benzinga
Perspective Therapeutics to Participate in Upcoming Investor Conferences in November - The Manila Times
Perspective Therapeutics' SWOT analysis: radiopharmaceutical stock's lead-212 edge - Investing.com India
Nuclear Medicine Market Size & Global Growth Report [2032] - Fortune Business Insights
1,602,283 Shares in Perspective Therapeutics, Inc. (NYSE:CATX) Purchased by Nicholson Wealth Management Group LLC - MarketBeat
Perspective Therapeutics (NYSE:CATX) Shares Gap UpStill a Buy? - MarketBeat
Perspective Therapeutics initiated with a Buy at UBS - TipRanks
Perspective Therapeutics (NYSE:CATX) Given Outperform Rating at Wedbush - MarketBeat
Market undervaluing Perspective Therapeutics stock amid upcoming trial data, says UBS - Investing.com
Perspective Therapeutics (NYSE:CATX) Now Covered by UBS Group - MarketBeat
Perspective Therapeutics presents updates at 37th Annual Congress of EANM - TipRanks
Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine - The Manila Times
Immunodeficiency Therapeutics Market Analysis by Industry - openPR
Capricor Therapeutics (NASDAQ:CAPR) shareholder returns have been enviable, earning 685% in 5 years - Simply Wall St
Oppenheimer maintains outperform rating on CATX shares amid new data - Investing.com India
Siemens Healthineers Gets FDA Clearance for Alzheimer’s Disease Analysis Features - Imaging Technology News
The Manufacturers Life Insurance Company Acquires 6,328 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Perspective Therapeutics Inc (CATX) Shares Up 4.38% on Oct 16 - GuruFocus.com
Perspective begins shipping investigational products from facility in NJ - TipRanks
Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey - The Manila Times
Perspective Therapeutics Begins Shipping Investigational Products from Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey - Marketscreener.com
Perspective Therapeutics (NYSE:CATX) Trading Up 4.9%Should You Buy? - MarketBeat
Perspective Therapeutics Inc (CATX) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Perspective Therapeutics stock rises despite initial confusion over VMT01 melanoma study results - Investing.com Australia
Perspective Therapeutics (NYSE:CATX) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Market Recap: Perspective Therapeutics Inc (CATX)’s Negative Momentum, Closing at 12.66 - The Dwinnex
Analyzing Perspective Therapeutics Inc (CATX) After Recent Trading Activity - Knox Daily
Perspective Therapeutics Inc (CATX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
0.43%
자본화:
|
볼륨(24시간):